Refine by
Immune Activating Articles & Analysis
50 news found
As reported by UCLA Health, a novel cancer vaccine could trigger robust immune responses in patients with pancreatic and colorectal cancer, driving a growing wave of research excitement around cancer vaccines. ...
Neutrophils are the most abundant white blood cells in the human body and among the very first immune cells to be recruited during inflammation. Yet despite their central role, their study has long been constrained by the lack of reliable tools to monitor their activity in real time. ...
A vaccine is a specialized biological formulation that triggers the immune system to recognize and activate protective responses against specific disease-causing agents. ...
The featured vaccine products supplied by Alfa Chemistry are listed as below: Nucleic Acid Delivery ExcipientsNucleotide vaccines, including mRNA vaccines with their intracellular antigen synthesis, have been shown to be potent activators of a cytotoxic immune response. However, the intracellular delivery of mRNA vaccines to the cytosol of antigen presenting ...
"Our AI platform basically mimics the human immune system using AI," said Ofran. "For this program, we chose the IL-2 pathway, which is well-studied and extensively explored. The antibody that is entering the clinic now was designed based on our understanding of the IL-2 pathway. We know IL-2 activates the immune system to attack the tumor, but ...
The financing will be used to advance NextPoint’s two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Additional new investors in the round include Invus, Catalio Capital Management, Sixty Degree Capital and PagodaTree Partners. ...
ByBayer AG
Under its subsidiary, OnkosXcel Therapeutics, the Company is developing BXCL701, an investigational, orally administered, systemic innate immune activator for the treatment of aggressive forms of prostate cancer. ...
Under its subsidiary, OnkosXcel Therapeutics, the Company is developing BXCL701, an investigational, orally administered, systemic innate immune activator for the treatment of aggressive forms of prostate cancer. ...
Emergent will begin the planning phase, the first of two phases, in collaboration with the Armed Forces Research Institute of Medical Sciences (AFRIMS) and academic partners, to enable a post-approval field efficacy study in areas with active chikungunya virus (CHIKV) transmission. “Emergent is pleased to gain the support of the CDMRP to verify the clinical benefit of our ...
Title: Dual targeting of innate and adaptive immune checkpoints with a PD-L1/SIRPα bispecific macrophage engager to promote anti-tumor activity Abstract No.: 1211 The anti-PDL1/SIRPα bispecific antibody ES019, designed for tumor cell and immune cell dual targeting, is capable of reactivating macrophages and T cells to kill cancer ...
RGT-264 phosphate tablet is a highly potent and selective HPK1 inhibitor. HPK1 kinase activity suppresses the immune functions of a wide range of cells including T cells and dendritic cells (DCs) 1. Therefore, inhibiting HPK1 activity serves as a promising approach for cancer immunotherapy. Currently, there is no HPK1 inhibitor approved globally. ...
About PMC-309 PMC-309 is a novel anti-VISTA (V-domain Ig Suppressor of T cell Activation) antagonizing antibody that can be used for the treatment of various tumor types. ...
Company announces completion of Phase 1 dose escalation ahead of schedule for IO-108, a first-in-class antibody targeting LILRB2 (ILT4) Signals of clinical activity observed in multiple tumor types for IO-108 as a single agent and in combination with an anti-PD-1 Immune-Onc Therapeutics, Inc. ...
ATG-101 is a novel PD-L1/4-1BB bispecific antibody that was designed to block the binding of immunosuppressive PD-1/PD-L1 and conditionally induce 4-1BB stimulation, thus activating anti-tumor immune effectors, while delivering enhanced anti-tumor activity, with an improved safety profile. In preclinical studies, ATG-101 demonstrated significant ...
Among the past years, we have continued to develop our third-party vaccine marketing and distribution activities further, notably with the signing of a distribution agreement with Bavarian Nordic in 2020, and we are extremely pleased to add VBI’s Hepatitis B vaccine to this portfolio today. ...
Under its subsidiary OnkosXcel Therapeutics, the Company is developing BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint ...
Under its subsidiary, OnkosXcel Therapeutics, the Company is developing BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint ...
AFM24 utilizes the patient’s innate immunity to redirect and activate immune cells, overcoming resistance to current therapies. ...
Preclinical data have shown that AFM24 can induce NK cell-mediated killing of EGFR-positive solid tumor cell lines, independent of EGFR mutational status. The analysis also showed activation of cytotoxic T cells in the periphery, and infiltration of T cells into the tumor bed, suggesting stimulation of anti-cancer immunity beyond the innate ...
ABOUT LILRB2 (ILT4) LILRB2, also known as ILT4, is expressed mostly by myeloid cells, including monocytes, macrophages, dendritic cells, and neutrophils. In solid tumors, activation of LILRB2 by its ligands, including HLA-G, ANGPTLs, SEMA4A, and CD1d, induces a tolerogenic phenotype in myeloid cells, thereby suppressing T cell activation and promoting tumor ...